News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • OpenAI will defer an IPO beyond 2026, citing safety and alignment concerns around rapidly advancing AI.
  • The delay removes a major potential AI IPO from the 2026 market calendar.
  • Investors in AI startups now face longer private-market holding periods and delayed exit timelines.
  • Anthropic plans to proceed with its own IPO timetable even as its CEO urges a slower pace of capability gains.
  • OpenAI's public postponement elevates political and regulatory focus on AI safety and governance.
  • Markets could reassess valuations and sector risk premia for AI companies after the deferral.

Latest Articles

Oil steadies as Hormuz shipping slows and U.S.-Iran talks remain stalled

Oil steadies as Hormuz shipping slows and U.S.-Iran talks remain stalled

Oil prices showed little movement in early trade as vessel traffic through the Strait of Hormuz slowed over the weekend and no agreement materialized to end the U.S.-Iran conflict. Brent ticked up modestly while U.S. crude slipped slightly, leaving markets to weigh supply disruption risks against informal routing and other stopgaps.

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Limited has completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. The trial treated 350 patients—exceeding the initial target—evaluating pain reduction and improvements in function and quality of life. The therapy has received RMAT designation from…

Nebius Breakout: Pricing Power Rewrites the Growth Story

Nebius Breakout: Pricing Power Rewrites the Growth Story

Nebius (NBIS) just re-priced. Strong net-loss improvement, $236M EBITDA, larger enterprise deals and an asset-light pivot have the market re-assessing growth economics. At a market cap of ~$69.9B the stock is richly valued, but a discrete set of catalysts and technical momentum create a tradeable long setup with defined risk controls over the next …

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

HUTCHMED announced that the global Phase III SAFFRON trial demonstrated that combining ORPATHYS® (savolitinib) with TAGRISSO® (osimertinib) significantly improved progression-free and overall survival in patients with MET-driven EGFR-mutated non-small cell lung cancer (NSCLC) after progression on TAGRISSO®. This represents a novel, biomarker-direct…

Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit, Supporting Globalstar Direct-to-Device Communications Services

Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit, Supporting Globalstar Direct-to-Device Communications Services

Rocket Lab Corporation announced the successful orbit insertion and commissioning of eight advanced satellite platforms built for MDA Space, part of a 17-satellite build contract supporting Globalstar's replenishment constellation. These satellites enable direct-to-device communications and IoT applications globally. The platforms are built on Rock…

Tariffs, Contracts and Momentum: Why RCAT's Rally Still Has Room to Run

Tariffs, Contracts and Momentum: Why RCAT's Rally Still Has Room to Run

Red Cat (RCAT) has a string of positive government wins and a macro policy tailwind from new tariffs that make a mid-term long trade attractive despite stretched valuation and negative cash flow. Entry at $11.12, stop at $9.25, target $16.50 over a mid-term (45 trading days) horizon. Risk management and close monitoring of program milestones are cr…

TTM Technologies: From Boring PCB Maker to AI-Fueled Growth Play

TTM Technologies: From Boring PCB Maker to AI-Fueled Growth Play

TTM Technologies has pivoted from cyclical PCB manufacturing to being a direct beneficiary of AI infrastructure buildouts. Recent results and Europe-focused acquisitions support revenue acceleration, while valuation still leaves room for upside if growth sustains. This trade idea outlines an actionable entry, stop, and target with clear catalysts a…

Buy Micron Now: KOSPI-Driven Panic Is a Better Entry Than a Warning

Buy Micron Now: KOSPI-Driven Panic Is a Better Entry Than a Warning

Micron (MU) is a buy on pullback. The stock trades at $972.98 after a sector wobble linked to KOSPI weakness. Fundamentals - $26.2B free cash flow, EPS $44.69, ROE 50% and a $1.1T market cap - support a long trade to $1,250 over the next 46-180 trading days. Entry $975, stop $820, target $1,250. Risk is real but manageable with tight sizing.

Church & Dwight: Buy for Volume-Led Growth and Margin Rebound

Church & Dwight: Buy for Volume-Led Growth and Margin Rebound

Church & Dwight ($101.33) offers a pragmatic buy: secular demand in laundry and sexual health categories, recent volume recovery, a conservative balance sheet (debt/equity ~0.52) and improving margins underpin a mid-term swing trade. Entry $101.00, target $110.00, stop $94.00 for a 45-trading-day plan with a medium risk profile.

Ituran: Buy the Dip — Q2 Cash Flow and Dividends Validate the Rebound

Ituran: Buy the Dip — Q2 Cash Flow and Dividends Validate the Rebound

Ituran’s combination of strong cash generation, a clean balance sheet and an active dividend policy argues for buying the recent dip. The business remains cash-rich with no bank debt, free cash flow of roughly $49M and recurring payouts that show management confidence. Technicals suggest room to run toward the 52-week high while downside can be con…

Buy the VMware Dip: Broadcom Looks Attractive After the Pullback

Buy the VMware Dip: Broadcom Looks Attractive After the Pullback

Broadcom (AVGO) has pulled back sharply amid VMware-related headlines, creating a buying opportunity in a high-quality cash-generative franchise. The business pairs durable semiconductor moat with Infrastructure Software cash flows; at the current price the stock offers a compelling asymmetry for long-term oriented traders willing to tolerate headl…

Tapestry Pullback Creates a Tactical Long: Coach's Momentum Is Mispriced

Tapestry Pullback Creates a Tactical Long: Coach's Momentum Is Mispriced

Tapestry's pullback since its 52-week high has pushed the stock below key moving averages and into oversold territory. Fundamentals - a $25.7B market cap, ~$1.8B in free cash flow and a recent $2.8B buyback - argue that the market is discounting the company’s cash conversion and brand resilience. This trade targets a mean-reversion rally over the n…